# Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment

> **NCT01724723** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Hepatitis
- Tuberculosis
- hepatitisB

## Interventions

- **DRUG:** entecavir (BARACLUDE®)

## Key facts

- **NCT ID:** NCT01724723
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2012-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724723, "Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01724723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*